

An Analytical Observational Study to Determine the Association between Serum Bilirubin Levels and Coronary Artery Disease

Mukesh Shandilya¹, Gautam Kumar²

¹Senior Resident (Academic) Department of Cardiology, IGIMS, PATNA, Bihar, India

²Assistant Professor, Department of Cardiology, IGIMS, PATNA, Bihar, India

Received: 09-02-2024 / Revised: 16-03-2024 / Accepted: 29-04-2024

Corresponding Author: Dr. Mukesh Shandilya

Conflict of interest: Nil

Abstract

Aim: The aim of the present study was to assess the association between serum bilirubin levels and coronary artery disease in comparison with controls without coronary artery disease.

Methods: The cross-sectional study was conducted for a period of a one year in IGIMS, PATNA, Bihar, India. The entire study subjects were divided into two groups of 50 cases (with CVD) and 50 controls.

Results: It was seen from the table that majority of the subjects were in the age group between 55 and 65 years. The minimum age was 43 and the maximum age was 75 years. The most common risk factors for CVD like diabetes, hypertension, smoking, obesity and family history of CVD was found to be slightly higher among the cases than the control groups but it was not found to be statistically significant and it proves that the controls were matched for almost all the risk factors for CVD except for dyslipidemia which was found to be significantly higher among the CVD patients than the controls. The duration of CVD among the cases varied from 2 years to 9 years with majority of the subjects' duration was between 3 and 5 years and the mean duration was 4.4 years. The various liver function test parameters were compared between the cases and controls it was found that the serum bilirubin levels which includes total bilirubin, direct bilirubin and indirect bilirubin was found to be lower among the case group compared to the control group and this difference was found to be statistically significant.

Conclusion: This study showed a significant association between the reduced serum bilirubin levels and the occurrence of CAD; therefore, bilirubin level can serve as a predictive factor, together with other influential factors for identifying a person at risk of developing coronary artery disease.

Keywords: Coronary artery disease, Ejection fraction, Risk factor, Serum bilirubin

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

The role of inflammation in cardiovascular disease (CVD) is established. Oxidative stress plays an important role in atherosclerosis, which is a chronic inflammatory response to vascular endothelial injury caused by a variety of factors promoting inflammatory cell entry and activation. [1] The recognition of bilirubin as an important endogenous anti-inflammatory and antioxidant molecule has increased in recent decades. Bilirubin affects atherosclerosis by several inhibiting mechanisms, including low-density lipoprotein oxidation, vascular smooth muscle cell proliferation, and endothelial dysfunction. Mildly elevated circulating bilirubin levels seems to represent a promising target for prevention and reduction of the prevalence of CVD and other oxidative-stress disorders, including type 2 diabetes mellitus (T2DM) and cancer. [2] Accordingly, the role of bilirubin as a biological predictor in the risk assessment of chronic disorders, with increasing worldwide prevalence, is of considerable medical economic importance. Indeed,

CVD represent a main cause of mortality and burden of disease. [3]

Recent meta-analysis has found an inverse association between total bilirubin levels and the risk of CVD, which is independent of established risk factors. [4] Thus, serum bilirubin level may be an independent marker for environmental and genetically determined CVD risk. The reported effects of bilirubin levels on an individual basis, however, have been inconsistent in the context of CVD. Increased bilirubin levels have been associated with greater protection against CVD in some studies [5,6], whereas other research indicates that higher levels of bilirubin have increased or null associations with CVD. [7,8]

Bilirubin is a heme degradation product. During the catabolism of hemoglobin, heme is converted into biliverdin by heme oxygenase which is acted upon by biliverdin reductase to form bilirubin. In liver cells, bilirubin is changed to a conjugated form for

secretion in bile juice. [9] At concentrations found in human plasma, bilirubin acts as an antioxidant to scavenge peroxy radicals as efficiently as alpha-tocopherol. [10,11] Both free and bound forms of bilirubin can inhibit the oxidation of low-density lipoproteins at physiological concentrations. [12,13] Oxidation of low-density lipoproteins is an important initial step in atherogenesis that can stimulate platelet aggregation and can alter vasomotor properties. [11] Gilbert's syndrome patients have a reduced risk of cardiovascular disease (CVD) which is associated with increased bilirubin levels and altered lipid and inflammatory profiles. [14] At pathological levels, unconjugated bilirubin inhibits cytotoxic T cell activity and proliferative responses to human peripheral blood mononuclear cells in patients with neonatal or obstructive jaundice. [15]

The aim of the present study was to assess the association between serum bilirubin levels and coronary artery disease in comparison with controls without coronary artery disease.

Materials and Methods

The cross-sectional study was conducted for a period of a one year in department of Cardiology , IGIMS, PATNA, Bihar, India.

Patients with evidence of coronary artery disease for not more than 10 years of duration confirmed by ECG, ECHO and other previous case records were taken as cases. The entire study subjects were divided into two groups of 50 cases (with CVD) and 50 controls.

Patients with symptoms of congestive cardiac failure, chronic kidney disease, chronic liver disease, autoimmune diseases, COPD and malignancy were excluded from the study. Controls

were selected matched with age, gender and other co-morbid conditions. Total of 200 subjects were included in the study with 100 cases and 100 controls. Informed consent was obtained from all the subjects involved in the study.

A complete socio-demographic details was obtained from all the subjects including the dietary habits and smoking/alcohol history. General and systemic examination was conducted on all study subjects including laboratory investigations like complete blood count, renal function test, lipid profile, viral markers such as HBsAG, HCV IgM and liver function test which includes total bilirubin, direct and indirect, liver enzymes, albumin and globulin levels. A 12 lead ECG and a transthoracic echocardiogram was performed for all patients.

Total serum bilirubin was measured in the laboratory by spectrophotometry method. In the Jendrassik-Grof allied methods, total bilirubin is reacted with diazotized sulfanilic acid in an acidic medium to form azobilirubin. The absorbance of the azo pigment is then measured as direct bilirubin and the total bilirubin is measured after treatment with alkaline tartrated solution, which shifts the maximum absorption of the azo pigment towards longer wavelength.

Statistical Analysis

All the data were entered and analysed using SPSS version 22. Mean and standard deviation was derived for all the parametric variables and the parametric variables between the two groups (cases and controls) were compared using unpaired student T test and comparison between the frequencies was done by using chi-square test considering p <0.05 as statistically significant.

Results

Table 1: Age and sex wise distribution of the study subjects

Age group	Cases		Controls		P value
	Males	Females	Males	Females	
40-45	2	1	2	0	0.624
46-50	3	1	4	1	
51-55	1	1	1	1	
56-60	11	3	12	4	
61-65	8	8	7	6	
66-70	5	2	5	1	
>70	2	2	5	1	
Total	32	18	36	14	
Mean±SD	64.9±8.6	65.5±8.2	63.7±8.4	62.8±8.5	

It was seen from the table that majority of the subjects were in the age group between 55 and 65 years. The minimum age was 43 and the maximum age was 75 years.

Table 2: Prevailing risk factors for CVD among study subjects

Risk factors	Cases (n=100)	Controls (n=100)	P value
Diabetes	16 (32%)	14 (28%)	0.323
Hypertension	28 (56%)	22 (44%)	0.160
Smoking	20 (40%)	18 (36%)	0.832
Family history of CVD	21 (42%)	16 (32%)	0.272
Obesity	14 (28%)	10 (20%)	0.188
Dyslipidemia	32 (64%)	21 (42%)	0.007

The most common risk factors for CVD like diabetes, hypertension, smoking, obesity and family history of CVD was found to be slightly higher among the cases than the control groups but it was not found to be statistically significant and it proves

that the controls were matched for almost all the risk factors for CVD except for dyslipidemia which was found to be significantly higher among the CVD patients than the controls.

Table 3: Distribution of the cases based on their duration of CVD

Duration of CVD	Frequency	Percentage	Mean±SD
<3 years	11	22	
3 -5 years	24	48	
5 -7 years	11	22	4.4±2.8
>7 years	4	8	
Total	50	100	

The duration of CVD among the cases varied from 2 years to 9 years with majority of the subjects' duration was between 3 and 5 years and the mean duration was 4.4 years. The patients' CVD status was confirmed by history, ECG findings and ECHO reports.

Table 4: Comparison of the liver function test parameters between the CVD patients and the controls

LFT	Cases (mean±SD)	Controls (mean±SD)	P value
Total bilirubin	0.88±0.07	1.25±0.22	<0.001
Direct bilirubin	0.24±0.06	0.49±0.07	<0.001
Indirect bilirubin	0.65±0.08	0.84±0.12	<0.001
SGOT (IU/L)	25	28	0.571
SGPT (IU/L)	29	33	0.219
GGT(IU/L)	31	29	0.313

The various liver function test parameters were compared between the cases and controls it was found that the serum bilirubin levels which includes total bilirubin, direct bilirubin and indirect bilirubin was found to be lower among the case group compared to the control group and this difference

was found to be statistically significant, whereas the other parameters like SGOT, SGPT and GGT levels did not show much difference between the case and control groups and the difference in values were not statistically significant.

Table 5: Association and correlation between serum bilirubin levels and the ejection fraction among the CVD patients

Serum bilirubin	>60%(n=14)	50-60%(n= 26)	<50% (n=10)	P-value
Total bilirubin(mean±SD)	1.1±0.34	0.86±0.24	0.72±0.17	<0.001
Direct bilirubin(mean±SD)	0.42±0.12	0.34±0.06	0.22±0.08	<0.001
Indirect bilirubin(mean±SD)	0.73±0.27	0.65±0.08	0.62±0.06	<0.001

For all the CVD patients an echocardiogram was performed and their ejection fraction was recorded and it was correlated with the serum bilirubin levels, authors found a perfect linear correlation between the ejection fraction and serum bilirubin levels, as the ejection fraction decreases the serum bilirubin levels was also decreasing and all the serum bilirubin parameters were found to be very low in

patients with ejection fraction <50% when compared to patients with ejection fraction >60% and this association was found to be statistically significant (p <0.05).

Discussion

Coronary artery diseases (CAD) is still the major Prevailing cause of mortality among advanced

countries. On the other hand, the number of CAD victims is continuously increasing in developing countries. [16] The remarkable prevalence of cardiovascular diseases in today's society highlights the necessity of the identification of risk factors and screening of vulnerable individuals in using preventive and treatment methods. [17] Although various main risk factors have been identified for atherosclerosis, including hypertension (HTN), hyperlipidemia, diabetes mellitus (DM), smoking, etc., for many years, the bile pigment bilirubin was considered to be only a toxic waste product formed during heme catabolism. [18-20]

The products of the catabolic reaction, i.e. bilirubin, carbon monoxide and iron have a protective role. The other important role of bilirubin, the natural antioxidants are the inhibition of vascular cell adhesion molecule VCAM-1 preventing the proliferation of the smooth muscle cells and the transendothelial migration of the leucocytes. [21] It was seen from the table that majority of the subjects were in the age group between 55 and 65 years. The minimum age was 43 and the maximum age was 75 years. Male gender is one of the most important risk factors for CAD. The same was found in our study. Males were predominant in cases and so we matched the controls accordingly. Authors also matched the cases and controls with regards to age and other comorbidities thereby removing the confounding factors responsible for the lowering of bilirubin as a result of the oxidative stress and other mechanisms. [22] The most common risk factors for CVD like diabetes, hypertension, smoking, obesity and family history of CVD was found to be slightly higher among the cases than the control groups but it was not found to be statistically significant and it proves that the controls were matched for almost all the risk factors for CVD except for dyslipidemia which was found to be significantly higher among the CVD patients than the controls.

The duration of CVD among the cases varied from 2 years to 9 years with majority of the subjects' duration was between 3 and 5 years and the mean duration was 4.4 years. The patients' CVD status was confirmed by history, ECG findings and ECHO reports. The various liver function test parameters were compared between the cases and controls it was found that the serum bilirubin levels which includes total bilirubin, direct bilirubin and indirect bilirubin was found to be lower among the case group compared to the control group and this difference was found to be statistically significant, whereas the other parameters like SGOT, SGPT and GGT levels did not show much difference between the case and control groups and the difference in values were not statistically significant. Several authors have suggested that bilirubin plays a potential role in inhibition of lipid oxidation. [23] An inverse correlation between the presence of

coronary artery disease, peripheral arterial disease, carotid intima-media thickness and bilirubin has been reported in several studies. Subnormal levels of plasma bilirubin are associated with premature coronary artery disease and cardiovascular morbidity. [24] In a previous study, the 3-year incidence of coronary artery disease was significantly lower in patients with Gilbert syndrome. [25]

For all the CVD patients an echocardiogram was performed and their ejection fraction was recorded and it was correlated with the serum bilirubin levels, authors found a perfect linear correlation between the ejection fraction and serum bilirubin levels, as the ejection fraction decreases the serum bilirubin levels was also decreasing and all the serum bilirubin parameters were found to be very low in patients with ejection fraction <50% when compared to patients with ejection fraction >60% and this association was found to be statistically significant ($p < 0.05$).

Conclusion

This study showed a significant association between the reduced serum bilirubin levels and the occurrence of CAD; therefore, bilirubin level can serve as a predictive factor, together with other influential factors for identifying a person at risk of developing coronary artery disease.

References

1. Gul M, Kalkan AK, Uyarel H. Serum bilirubin: a friendly or an enemy against cardiovascular diseases? *Journal of critical care*. 2014;29(2):305–6.
2. Wagner KH, Wallner M, Molzer C, Gazzin S, Bulmer AC, Tiribelli C, et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. *Clinical science*. 2015;129 (1):1–25.
3. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–71.
4. Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. *Arteriosclerosis, thrombosis, and vascular biology*. 2015;35(3):716–24.
5. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. *The American journal of cardiology*. 2001;87(10): 1196–200.
6. Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of

- stroke incidence: a prospective study in Korean men and women. *Stroke; a journal of cerebral circulation*. 2009;40(11):3422-7.
7. Schooling CM, Kelvin EA, Jones HE. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. *Annals of epidemiology*. 2012;22(11):789-98.
 8. Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. *Cancer causes & control: CCC*. 2001;12(10):887-94.
 9. Gupta N, Singh T, Chaudhary R, Garg SK, Sandhu GS, Mittal V, Gupta R, Bodin R, Sule S. Bilirubin in coronary artery disease: Cytotoxic or protective?. *World journal of gastrointestinal pharmacology and therapeutics*. 2016 Nov 11;7(4):469.
 10. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. *Proc Natl Acad Sci U S A*. 1987 Aug;84(16):5918-22.
 11. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. *J Biol Chem*. 1994 Jun 17;269(24):16712-9.
 12. Hulea SA, Wasowicz E, Kummerow FA. Inhibition of metal-catalyzed oxidation of low-density lipoprotein by free and albumin-bound bilirubin. *Biochim Biophys Acta*. 1995 Oct 26;1259(1):29-38.
 13. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. *Biochemical pharmacology*. 1996 Mar 22;51(6):859-62.
 14. Wallner M, Marculescu R, Doberer D, Wolzt M, Wagner O, Vitek L, Bulmer AC, Wagner KH. Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome. *Clinical Science*. 2013 Sep 1;125(5):257-64.
 15. Haga Y, Tempero MA, Zetterman RK. Unconjugated bilirubin inhibits in vitro cytotoxic T lymphocyte activity of human lymphocytes. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease*. 1996 Oct 7;1317(1):65-70.
 16. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. *Annu Rev Pathol. Mech Dis*. 2006 Feb 28;1:297-329.
 17. Louise D. Bilirubin protects against heart disease. *Medical Xpress*. 2012.
 18. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. *Clin Chem*. 2000 Nov 1;46(11):1723-7.
 19. Muraca M, Fevery J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. *Gastroenterol*. 1984 Aug 1;87(2):308-13.
 20. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. *Clin Chem*. 1994 Jan 1;40(1):18-23.
 21. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. *Journal of Biological Chemistry*. 1994 Jun 17;269(24):16712-9.
 22. Ghem C, Sarmento-Leite RE, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. *International heart journal*. 2010;51(2):86-91.
 23. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. *Proceed NationalAcademySci*. 1987Aug1;84(16):5918-22.
 24. Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. *Stroke*. 2001 Feb 1;32(2):580-3.
 25. Vitek L, Jirsa Jr M, Brodanová M, Kaláb M, Mareček Z, Danzig V, Novotný L, Kotal P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. *Atherosclerosis*. 2002 Feb 1;160(2):449-56.